Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind

Erasca shares rose 8 percent on Wednesday to $12.43 as biotech traders positioned ahead of the American Society of Clinical Oncology annual meeting in Chicago, where the precision oncology company is expected to feature in the RAS-targeted therapy discussion. The move continues a rebuild from late April, when the stock lost nearly half its value on an intellectual property challenge from Revolution Medicines and disclosure of a patient death in a clinical trial. Erasca is a clinical-stage company building a franchise around RAS/MAPK pathway-driven cancers, and the next major catalyst is preliminary Phase 1 monotherapy data from its second program, ERAS-4001, expected in the second half of 2026.

What does Erasca actually do and why does the pan-RAS approach attract so much capital?

Erasca is a San Diego-based precision oncology company singularly focused on therapies for cancers driven by mutations in the RAS/MAPK signaling pathway. RAS mutations are among the most common drivers of human cancer, present in roughly 2.2 million new diagnoses each year worldwide, and they have historically been considered undruggable. The company is pursuing two lead programs that take different shots at the same biology, ERAS-0015 and ERAS-4001.

ERAS-0015 is a pan-RAS molecular glue, an oral drug designed to bind a chaperone protein called cyclophilin A and effectively glue it to RAS, shutting down signaling. The technical pitch is that a molecular glue can hit multiple RAS mutations rather than only one, and Erasca’s preclinical data positioned it as roughly 8 to 21 times more potent in binding affinity than Revolution Medicines’ competing compound RMC-6236. ERAS-4001 is a pan-KRAS inhibitor that targets KRAS broadly while sparing the HRAS and NRAS isoforms, with the goal of a better safety window.

The retail investor angle is that the entire field is being repriced in real time. RAS-targeted oncology is one of the largest unmet need categories in cancer, and a credible best-in-class candidate from a small-cap biotech can re-rate sharply on any positive data point. The flip side is that a competitor IP challenge or a clinical setback can take half the equity out of a company in a single session, which is exactly what happened to Erasca in April.

Why did Erasca shares lose half their value in late April before recovering?

On April 27, Erasca delivered the long-awaited Phase 1 dose escalation readout for ERAS-0015 and the headline efficacy numbers were strong. In KRAS G12X non-small cell lung cancer, the company reported a 62 percent unconfirmed overall response rate in second-line-plus patients at the 16 to 32 mg once daily dose range, and a 75 percent rate in a post-immunotherapy and post-platinum subset. In KRAS G12X pancreatic ductal adenocarcinoma, second-line patients showed a 40 percent unconfirmed response rate at the same dose range, rising to 50 percent at 32 mg.

Despite those headline numbers, the stock sold off sharply because two issues overshadowed the data. Revolution Medicines raised an IP challenge alleging that ERAS-0015 infringes its patents or was derived from its trade secrets, a dispute Erasca disclosed in its own risk factors. Separately, reports emerged of a patient death in the trial. The combination of legal risk and a safety question against a freshly released dataset triggered a roughly 50 percent decline in the days that followed.

The execution risk this exposes is structural for any clinical-stage biotech. Even a strong data readout cannot protect a stock from a credible legal challenge or a safety signal that traders cannot quickly verify. For retail investors, the lesson is that Phase 1 biotech catalysts are bidirectional even when the efficacy numbers look good, and the headline response rates are only the first variable the market prices.

How does the May Merck Keytruda collaboration change the ERAS-0015 development plan?

In May 2026, Erasca announced a Clinical Trial Collaboration and Supply Agreement with Merck, the company known as MSD outside the United States and Canada, to evaluate ERAS-0015 in combination with the anti-PD-1 therapy KEYTRUDA. Under the agreement, Merck supplies pembrolizumab at no cost and Erasca remains the trial sponsor. This is the second pharma collaboration around ERAS-0015 in 2026, following a March deal with Tango Therapeutics to evaluate the molecule in combination with the EZH2 inhibitor vopimetostat.

What this signals is that ERAS-0015 is being positioned as a combination backbone rather than a standalone monotherapy. Preliminary data presented in April suggested the drug could be combined safely with standard-of-care doses of panitumumab, a colorectal cancer therapy, with one out of one unconfirmed partial response in a small CRC cohort. Adding Keytruda extends the combination optionality into the immuno-oncology space, where checkpoint inhibitors have plateaued in many tumor types and a RAS-targeted partner could provide a differentiated mechanism.

The implication for retail investors is that the commercial thesis is broadening. A monotherapy story is binary, the drug works or it does not. A backbone-of-combinations story creates multiple shots on goal, with each partnership providing a potential path to differentiated efficacy. That said, combination trials are slower and more capital-intensive, and dilution risk grows alongside the trial footprint.

Why does the ASCO 2026 meeting matter so much for ERAS shareholders this week?

The American Society of Clinical Oncology annual meeting runs from May 29 to June 2 in Chicago, and it is the single most important conference for oncology stocks each year. Erasca did not disclose a peer-reviewed presentation in the same manner as a major data drop, but biotech traders routinely position ahead of the conference because side meetings, investor presentations, and competitor data can all shift sentiment on a name. Wednesday’s move likely reflects positioning ahead of that window rather than a discrete corporate announcement.

The wider context is that the RAS-targeted field will be heavily featured at ASCO 2026, with Revolution Medicines, Bristol Myers Squibb, Amgen, and Mirati-derived programs all expected to update on their own KRAS and pan-RAS molecules. Erasca’s competitive position will be judged against the data those names present, not just its own previously released numbers. A favorable comparison would extend the rally that began in early May, while a stronger showing from a competitor could compress the relative premium.

Execution risk here is that the company has already provided its headline dose escalation numbers and the next material data drop is the expansion and combination escalation cohorts in the first half of 2027. ASCO 2026 is a sentiment event, not a data event, which means any rally into the conference can unwind quickly if the company’s competitors deliver stronger headlines on the same days.

What does Erasca’s balance sheet say about its ability to reach the next data readout?

Erasca finished March 31, 2026 with approximately $409 million in cash, cash equivalents, and marketable securities, which the company says is sufficient to fund operations into the second half of 2028. That runway was extended materially by the January 2026 upsized public offering, which raised gross proceeds of $225 million at $10.00 per share, with underwriters subsequently exercising their option for additional shares.

The Q1 2026 report showed a net loss per share of 60 cents against a Wall Street estimate of 23 cents, a wide miss driven by accelerated R&D spending as both ERAS-0015 and ERAS-4001 advanced through clinical milestones. The company also announced in March that it would terminate its agreement with Novartis covering the naporafenib program, with the termination effective June 3, 2026. That decision concentrates the pipeline on the two RAS-targeted assets and removes a non-core program that had absorbed resources.

For retail investors the takeaway is that funding is not the near-term constraint. With a runway extending two years past the next major catalyst, Erasca is positioned to deliver the ERAS-4001 readout in the second half of 2026 and the ERAS-0015 expansion data in the first half of 2027 without forced equity raises. That said, biotechs at this stage frequently issue stock opportunistically into share price strength, so dilution remains a possibility rather than a certainty.

Where do analysts and short interest sit on Erasca after the rebuild?

Sell-side coverage is broadly constructive. Stifel raised its price target to $30 from $20, and Jefferies reiterated a Buy rating with a $21 price target, citing ASCO 2026 as a potential milestone. Mizuho lowered its target to $26 from $28 around the time of the May 11 earnings print but maintained a Buy rating. The mean 12-month price target sits around $20.70, with a high estimate of $30 and a low of $9, against the current price near $12.43. Eight analysts recommend buying the stock, one suggests selling.

That target dispersion of more than three to one is unusually wide and reflects the binary nature of biotech valuation. The bulls are pricing the pan-RAS thesis as a multi-billion-dollar commercial opportunity, while the bears are weighting the competitive intensity of the RAS field and the Revolution Medicines IP overhang. Both views can be internally consistent given the same dataset, which is why ASCO and the H2 2026 ERAS-4001 readout will move the stock substantially in one direction or the other.

For retail investors active on biotech-focused forums and social channels, Erasca has become a frequently discussed name in the precision oncology category. The combination of a clear lead program, a credible second asset, and a controversial IP dispute creates the kind of debate that drives volume and volatility, which is the environment in which retail positioning tends to matter most.

Key takeaways: What should investors watch as Erasca heads into ASCO 2026 and the second half catalysts?

• ERAS rose 8.09 percent to $12.43 on May 27 ahead of the ASCO 2026 meeting in Chicago, rebuilding from a roughly 50 percent decline in late April driven by a Revolution Medicines IP challenge and a clinical trial patient death disclosure.
• ERAS-0015 is the lead pan-RAS molecular glue program, with April 2026 Phase 1 dose escalation data showing a 62 percent unconfirmed response rate in KRAS G12X NSCLC and 40 percent in second-line PDAC.
• A May 2026 Clinical Trial Collaboration and Supply Agreement with Merck adds KEYTRUDA combination work to ERAS-0015’s development plan, alongside an existing Tango Therapeutics combination with vopimetostat.
• ERAS-4001, the pan-KRAS inhibitor, has preliminary Phase 1 monotherapy data expected in the second half of 2026, with the next ERAS-0015 expansion and combination readout pushed to the first half of 2027.
• The company finished Q1 2026 with $409 million in cash, funding operations into the second half of 2028, with the January 2026 $225 million upsized offering having materially extended the runway.
• Analyst sentiment is broadly bullish but with wide target dispersion, ranging from $9 to $30, reflecting genuine disagreement about whether the pan-RAS thesis is best-in-class or competitively crowded.
• The Revolution Medicines IP dispute remains the largest non-clinical risk and could resurface at any point through depositions, motions, or further public claims.